Full-Time

Research Engineer

LLMs and Generative Models

Posted on 10/31/2025

GenBio AI

GenBio AI

51-200 employees

AI-powered biological simulation for drug development

Compensation Overview

$170k - $260k/yr

Palo Alto, CA, USA

In Person

Category
AI & Machine Learning (2)
,
Requirements
  • M.S. or equivalent practical experience in MLOps, Computer Science, Engineering, or related field.
Responsibilities
  • Design and own AIDO’s internal model ecosystem, including scalable infrastructure for serving, finetuning, distillation, and inference across many model sizes and architectures.
  • Develop reusable pipelines for on-demand model finetuning using internal and external datasets, ensuring reproducibility and cost-efficiency.
  • Build APIs and inference tools that integrate deeply with downstream biology simulators.
  • Productionize foundation model interfaces, including transformer-based LLMs and diffusion/auto-regressive architectures, with an emphasis on biological data modalities (DNA, RNA, protein, etc.).
  • Collaborate with research and product teams to enable virtual experiments powered by generative AI, including agentic workflows and user-facing tooling.
  • Support distillation, quantization, and routing strategies to optimize model throughput and enable multi-model orchestration.
  • Prioritize observability, reliability, and safety in generative workflows through better logging, traceability, and rollback mechanisms.
  • Ensure scalability and automation throughout the model lifecycle: training, testing, deployment, and adaptation.
  • Automate everything.
Desired Qualifications
  • Ph.D. degree in Computer Science, Engineering, or related field. Experience in life sciences or healthcare is a plus.
  • Experience with biological data modalities (e.g., DNA, RNA, protein sequences, cell imaging).
  • Prior work on multimodal or multiscale models across text, sequences, images, or structure.
  • Background in model distillation, quantization, and memory/latency optimization.
  • Knowledge of RESTful API design and data security.
  • Strong written and verbal communication skills, especially across research, product, and engineering.
  • Deep curiosity about biology and excitement to build tools that democratize access to scientific exploration.

GenBio AI develops a digital organism called AIDO to simulate biological processes for drug development and personalized medicine. AIDO uses multiscale models to predict how molecules and cells behave, allowing researchers to test millions of potential treatments digitally to find the most effective options. Unlike traditional methods that rely heavily on physical trials, this platform provides actionable insights across multiple biological levels to improve vaccine safety and clinical diagnostics. The company's goal is to accelerate the creation of new medicines and minimize adverse reactions through partnerships with healthcare providers and research institutions.

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

Palo Alto, California

Founded

2024

Simplify Jobs

Simplify's Take

What believers are saying

  • Phase 1 AIDO released six foundation models covering 796 species for rapid simulations.
  • Employee count reached 21-50 with $3.7M revenue and $11.8M valuation since 2024.
  • Global offices in California, Paris, and Abu Dhabi expand partnership opportunities.

What critics are saying

  • Insilico's 18 AI drugs in trials, including Phase 3 INS018_055, outpace AIDO in 6-12 months.
  • Recursion's 25 petabytes data and 200+ programs crush GenBio's unvalidated models in 12-18 months.
  • FDA January 2026 guidance mandates Phase 2 validation, halting AIDO adoption in 9-15 months.

What makes GenBio AI unique

  • AIDO simulates millions of treatments using multiscale foundation models from DNA to cells.
  • Dr. Ziv Bar-Joseph leads multiscale model integration for drug discovery since February 2025.
  • Dr. Emma Lundberg drives data strategy as Co-Founder since June 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Remote Work Options

Flexible Work Hours

Paid Vacation

Unlimited Paid Time Off

Hybrid Work Options

Wellness Program

Mental Health Support

Professional Development Budget

Conference Attendance Budget

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-7%
PR Newswire
Jun 17th, 2025
Genbio Ai Welcomes Emma Lundberg As Co-Founder And Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ -- GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.In this role, Lundberg will focus on the development of GenBio AI's data strategy and other scientific initiatives, advancing its mission to build a generative digital organism

AI Magazine
Jun 17th, 2025
GenBio AI Welcomes Emma Lundberg as Co-Founder and Chief Scientific Advisor

PALO ALTO, Calif., June 17, 2025 /PRNewswire/ - GenBio AI, a company building the World's First AI-Driven Digital Organism (AIDO), is proud to announce that Dr. Emma Lundberg has formally joined the company as Co-Founder and Chief Scientific Advisor.

GenBio AI
May 7th, 2025
How moscot Maps Cells Through Time, Space, and Modality by Dominik Klein

In this talk, Dominik Klein presents "Mapping cells through time and space with moscot" at the Foundation Models for Biology Seminar Series by GenBio AI.

PR Newswire
Feb 28th, 2025
Genbio Ai Expands Global Leadership With Ziv Bar-Joseph As Co-Founder And Chief Scientific Officer

PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited to announce that Dr. Ziv Bar-Joseph has joined as Co-founder and Chief Scientific Officer.In this role, Bar-Joseph will lead work focused on the integration and use of GenBio AI's multiscale foundation models, ensuring they drive real impact in drug discovery, medicine, and beyond. His leadership will be pivotal in helping the company transform AI applications in biology and push the boundaries of biological research.Bar-Joseph brings extensive expertise from Sanofi, a leading global pharmaceutical company. As the VP and Head of R&D Data and Computational Sciences, he led multidisciplinary teams in machine learning, computational biology, and data science to accelerate drug and vaccine discovery. He is also the FORE Systems Professor of Computer Science at Carnegie Mellon University (CMU), specializing in biological systems modeling, and AI applications in genomics and systems biology

INACTIVE